The Association of Endothelin-1 with Early and Long-Term Mortality in COVID-19
- PMID: 38003873
- PMCID: PMC10672100
- DOI: 10.3390/jpm13111558
The Association of Endothelin-1 with Early and Long-Term Mortality in COVID-19
Abstract
(1) Background: Endothelial dysfunction is a key mechanism in the pathogenesis of COVID-19. High endothelin-1 during COVID-19 is associated with severe complications and increased mortality rates during hospitalization. This study is aimed to investigate the association of endothelin-1 levels with the risk of 30-day and 12-month all-cause mortality in patients with prior COVID-19. (2) Methods: A prospective study was conducted involving patients with COVID-19 in Karaganda, Kazakhstan. The level of endothelin-1 in the blood serum was evaluated by ELISA. Univariate and multivariate Cox regression was used to determine factors and significance of endothelin-1 associated with the risk of mortality within 30 and 365 days from hospitalization. (3) Results: The median endothelin-1 was higher in the group of patients who passed away within 30 days. The group showed statistically significant differences when compared to healthy volunteers from the control group (p = 0.0001), surviving patients (p = 0.001), and those who passed away within a year (p = 0.002). (4) Conclusions: Endothelin-1 levels are associated with increased mortality risk during the acute period of COVID-19, while plasma endothelin-1 level association with COVID-19 survivor mortality risk does not persist after 12 months.
Keywords: COVID-19; endothelial dysfunction; endothelin-1; mortality.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Association of endothelial activation assessed through endothelin-I precursor peptide measurement with mortality in COVID-19 patients: an observational analysis.Respir Res. 2021 May 13;22(1):148. doi: 10.1186/s12931-021-01742-8. Respir Res. 2021. PMID: 33985491 Free PMC article.
-
Association of sTREM-1 and Neutrophil-to-Lymphocyte Ratio as Prognostic Markers in COVID-19 Short- and Long-Term Mortality.J Inflamm Res. 2023 Dec 4;16:5807-5817. doi: 10.2147/JIR.S435305. eCollection 2023. J Inflamm Res. 2023. PMID: 38076336 Free PMC article.
-
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19.Thromb Res. 2022 Jan;209:106-114. doi: 10.1016/j.thromres.2021.11.027. Epub 2021 Dec 4. Thromb Res. 2022. PMID: 34922160 Free PMC article.
-
Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis.Clin J Am Soc Nephrol. 2020 Jun 8;15(6):784-793. doi: 10.2215/CJN.11130919. Epub 2020 May 7. Clin J Am Soc Nephrol. 2020. PMID: 32381583 Free PMC article.
-
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.JACC Heart Fail. 2017 May;5(5):317-326. doi: 10.1016/j.jchf.2017.02.021. JACC Heart Fail. 2017. PMID: 28449795 Review.
Cited by
-
Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome.Int J Mol Sci. 2024 Oct 2;25(19):10640. doi: 10.3390/ijms251910640. Int J Mol Sci. 2024. PMID: 39408968 Free PMC article.
References
-
- WHO Director-General’s Opening Remarks at the Media Briefing. [(accessed on 5 May 2023)]. Available online: https://www.who.int/news-room/speeches/item/who-director-general-s-openi....
Grants and funding
LinkOut - more resources
Full Text Sources